Stocktoria
Pyxis Oncology, Inc. PYXS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-08
Pyxis Oncology, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -609.2% | -554.1% | — | — | — |
| Net margin | -574.5% | -478.9% | — | — | — |
| FCF margin | -458.3% | -358.7% | — | — | — |
| Return on assets | -87.0% | -49.2% | -42.5% | -57.1% | -27.1% |
| Return on equity | -149.1% | -64.0% | -58.7% | -75.1% | -29.1% |
| Current ratio | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 |
| Revenue growth | -14.2% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001782223 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.